A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, drug effects, drug levels and preliminary antitumor activity of BMS-986416 when administered alone and in combination with Nivolumab in participants with select advanced solid tumors.
Checked against the public recordLast updated Apr 9, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Bristol-Myers Squibb
- Interventions being studied
- Drug: BMS-986416; Drug: Nivolumab
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Participants with histologically or cytologically confirmed locally advanced unresectable, metastatic, or recurrent select solid tumor * Eligible tumor types Non-small cell lung cancer (NSCLC), Urothelial carcinoma (UC), Squamous cell carcinoma of the head and neck (SCCHN), Hepatocellular carcinoma (HCC), Microsatellite-stable colorectal carcinoma (MSS CRC), or Pancreatic ductal adenocarcinoma (PDAC) * Resistant/refractory to or intolerant of existing standard therapies known to provide clinical benefit * Measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1) * Disease amenable to serial biopsy Exclusion Criteria: * Uncontrolled or significant cardiovascular disease * Known connective tissue disease such as Marfan, Ehlers-Danlos, or Loeys-Dietz syndrome * Medical requirement for chronic anticoagulant or antiplatelet agents (except low-dose aspirin, which is permitted) Other protocol-defined inclusion/exclusion criteria apply
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Local Institution - 0006Atlanta, Georgia
- Local Institution - 0005Baltimore, Maryland
- Local Institution - 0002Hackensack, New Jersey
- Local Institution - 0013Cleveland, Ohio
- Local Institution - 0003Pittsburgh, Pennsylvania
- Local Institution - 0004Houston, Texas
- Local Institution - 0021Ciudad Autónoma de Buenos Aires, Buenos Aires
- Local Institution - 0027ABB, Buenos Aires F.D.
- Local Institution - 0022CABA, Buenos Aires F.D.
- Local Institution - 0043Edegem, Antwerpen
- Local Institution - 0016Ghent, Oost-Vlaanderen
- Local Institution - 0009Edmonton, Alberta
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 9, 2025. Always confirm current availability with the study team.